Evaluating the Efficacy of I-fiber Pearl on Reducing Body Fat Accumulation in Obese Subjects
1 other identifier
interventional
50
1 country
1
Brief Summary
The aim of this study is to investigate the effects of I-Fiber Pearl on Body Weight and Body Fat in Obese Adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Nov 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2023
CompletedFirst Submitted
Initial submission to the registry
January 3, 2024
CompletedFirst Posted
Study publicly available on registry
January 12, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 18, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2024
CompletedDecember 27, 2024
December 1, 2024
11 months
January 3, 2024
December 25, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Change from baseline body weight at week 12
Compared the difference of body weight between the week 12 and 0.
Week 0, Week 12
Change from baseline body fat at week 12
Compared the difference of body fat between the week 12 and 0.
Week 0, Week 12
Study Arms (2)
placebo
PLACEBO COMPARATORPlacebo 200g, without any ingredients of inulin fiber. Eat 200g for once, and once a day.
I-Fiber Pearl
EXPERIMENTALI-Fiber Pearl 200g, with inulin fiber. Eat 200g for once, and once a day.
Interventions
Eligibility Criteria
You may qualify if:
- female
- aged 20-50 years old
- body mass index is greater than or equal to 27 kg/m2
- waist greater than or equal to 80 cm
You may not qualify if:
- Subjects diagnosed with cancer and on curative care.
- Subjects diagnosed with heart disease and on curative care.
- Subjects who use other drugs whose pharmacological effects may affect the experiment or may aggravate the effects of the drug.
- Subjects with systemic infection requiring antibiotics.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Chung Shan Medical Universitylead
- ITSWAY BIOTECH INC.collaborator
Study Sites (1)
Chung Shan Medical University
Taichung, South, 402, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Chin-Lin Hsu, Ph.D.
Chung Shan Medical University
- PRINCIPAL INVESTIGATOR
Chin-Lin Hsu, Ph.D.
Chung Shan Medical University
- PRINCIPAL INVESTIGATOR
Shiuan-Chih Chen, Dr.
Chung Shan Medical University
- PRINCIPAL INVESTIGATOR
Hung-Hsuan Kuo, Master
Chung Shan Medical University
- PRINCIPAL INVESTIGATOR
Chun-Tse Tsai, Master
Chung Shan Medical University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 3, 2024
First Posted
January 12, 2024
Study Start
November 1, 2023
Primary Completion
September 18, 2024
Study Completion
September 30, 2024
Last Updated
December 27, 2024
Record last verified: 2024-12